Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3853661 | 1.00 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3852786 | 0.77 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3852788 | 0.77 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL16464687 | 0.77 | NPC1 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL16464688 | 0.77 | NPC1 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3851504 | 0.77 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3852291 | 0.77 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3852286 | 0.77 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3851702 | 0.77 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 | |
| SCHEMBL3851501 | 0.77 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRM5CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579349-B2 | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-08-25 | — | — | US | disclosed |
| EP-1678169-B1 | 4-(PYRAZOL-3-YLAMINO)PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | EP | disclosed |
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037888-A1 | anticarcinogenic agent 5-Chloro-2-{2-[3-(pyrid-2-yl)isoxazol-5-yl]pyrrolidin-1-yl}-4-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine; chemical synthesis; use in modulating insulin-like growth factor 1 receptor activity | IGF1R, IGFBP1, GPR119 | CHRNB2 3865/4885CHRNA4 3879/4885CHRM5 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.